Technologies
PDF


WARF: P100349US02

Crystallized Vitamin D Analog 2-Methylene-18,19-Dinor-1Alpha-Hydroxy-Homopregnacalciferol


INVENTORS -

Hector DeLuca, James Thoden, Hazel Holden, Rafal Barycki

The Wisconsin Alumni Research Foundation (WARF) is seeking commercial partners interested in developing the vitamin D analog known as 2-methylene-18,19-dinor-1α -hydroxy-homopregnacalciferol for pharmaceutical use.
OVERVIEWThe hormonally active form of vitamin D, known as calcitriol or 1,25 dihydroxyvitamin D3, has shown promise for treating diseases ranging from osteoporosis to cancer to psoriasis. However, the hormone mobilizes calcium from bones and increases intestinal absorption of dietary calcium. Effective therapeutic concentrations can lead to hypercalcemia; a condition characterized by elevated blood calcium levels, alterations in mental status, muscle weakness and calcification of soft tissues and organs such as the heart and kidneys. Therefore, a need exists for non-calcemic compounds that provide desirable therapeutic effects without causing dose-limiting hypercalcemia.

UW–Madison researchers previously developed a vitamin D analog, 2-methylene-18,19-dinor-1α-hydroxy-homopregnacalciferol. This compound exhibits relatively high binding to vitamin D receptors, very low intestinal calcium transport activity, and very low ability to mobilize calcium from bone. It also displays relatively high cell differentiation activity, making it potentially useful as an anti-cancer agent or a therapeutic agent for treating skin conditions. However, it must be purified before it can be used as a pharmaceutical.
THE INVENTIONUW–Madison researchers now have developed a method using precipitation with hexane from ethyl acetate. This efficient process removes most of the contaminants, resulting in a highly pure product. Crystals acceptable for X-ray experiment also can be obtained using hexane from benzene via diffusion exchange.
APPLICATIONS
  • Production of highly pure 2-methylene-18,19-dinor-1α-hydroxy-homopregnacalciferol for use as a pharmaceutical
KEY BENEFITS
  • Crystallization process occurs easily and efficiently.
  • Solvent mixture is easy to remove.
  • Precipitated crystals are large enough to be recovered via filtration or other means.
ADDITIONAL INFORMATION
For More Information About the Inventors
Contact Information
For current licensing status, please contact Rafael Diaz at rdiaz@warf.org or 608-960-9847.
The WARF Advantage

WARF: A Leader in Technology Transfer Since 1925
Since its founding as a private, nonprofit affiliate of the University of Wisconsin–Madison, WARF has provided patent and licensing services to UW–Madison and worked with commercial partners to transform university research into products that benefit society. WARF intellectual property managers and licensing staff members are leaders in the field of university-based technology transfer. They are familiar with the intricacies of patenting, have worked with researchers in relevant disciplines, understand industries and markets, and have negotiated innovative licensing strategies to meet the individual needs of business clients.

The University of Wisconsin and WARF –
A Single Location to Accelerate Translational Development of New Drugs

UW–Madison has the integrative capabilities to complete many key components of the drug development cycle, from discovery through clinical trials. As one of the top research universities in the world, and one of the two best-funded universities for research in the country, UW–Madison offers state-of-the-art facilities unmatched by most public universities.

These include the Small Molecule Screening Facility at the UW Comprehensive Cancer Center; the Zeeh Pharmaceutical Experiment Station, which provides consulting and laboratory services for developing formulations and studying solubility, stability and more; the Waisman Clinical Biomanufacturing Facility; the Wisconsin Institute for Medical Research, which provides UW–Madison with a complete translational research facility; and the innovative, interdisciplinary Wisconsin Institutes for Discovery, home to the private, nonprofit Morgridge Institute for Research and its public twin, WID, part of the university's graduate school. The highly qualified experts at these facilities are ready to work with you to create a library of candidates for drug development.